Pay in 4 interest-free payments of $5.04 Learn more
Ships within 48 hours · Estimated delivery Aug 31 - Sep 5
MASH and the unmet need for GLP-1 therapies MASH is a progressive condition that develops in people who are overweight or living with obesity
It is expected to lead to expanded indications for semaglutide (potentially an indication for reduction of CV risk in obese patients)
Thangavelu T, Lyden E, Shivaswamy V
Participants were randomly assigned to receive maximum tolerated doses of either tirzepatide (10mg or 15mg) or semaglutide (1.7mg or 2.4mg) weekly for 72 weeks
US$ 28.10
US$ 21.80
US$ 27.64
US$ 29.79
US$ 22.94
US$ 20.40
US$ 21.71
US$ 26.68
US$ 21.66
US$ 27.83
